Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 30, 2017 18:56 ET | Source: Versartis

Versartis’ Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Multiple Oral and Poster Presentations at ENDO 2017

36-month data in pediatric GHD, showing consistent safety and efficacy profile through 3 years of treatmentBaseline characteristics of Phase 3 VELOCITY study population comparable to Phase 2Additional...
November 07, 2016 07:30 ET | Source: Versartis

Versartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS & IGF Society

MENLO PARK, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
November 03, 2016 16:05 ET | Source: Versartis

Versartis Reports Third Quarter 2016 Financial Results

MENLO PARK, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel,...
October 31, 2016 08:30 ET | Source: Versartis

Versartis to Present at Two Investor Conferences in November

MENLO PARK, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
September 28, 2016 09:02 ET | Source: Versartis

Versartis Announces Pricing of Follow-On Offering

MENLO PARK, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
September 27, 2016 16:01 ET | Source: Versartis

Versartis Announces Proposed Offering of Common Stock

MENLO PARK, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
September 26, 2016 07:00 ET | Source: Versartis

Versartis Initiates Phase 3 Trial of Somavaratan in Japan for Children with Growth Hormone Deficiency Following Completion of Phase 2

MENLO PARK, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
September 12, 2016 08:30 ET | Source: Versartis

Versartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting

MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
September 06, 2016 08:35 ET | Source: Versartis

Versartis to Present at the Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...
September 06, 2016 08:30 ET | Source: Versartis

Versartis to Host Investor Symposium Featuring Leading Experts in Growth Hormone Deficiency

MENLO PARK, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting...